The Claim

Myostatin enhances osteoclast formation in vitro by activating the SMAD2-NFATC1 signaling pathway downstream of RANKL.

Source: Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
14score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

Myostatin increases the formation of bone-resorbing cells in laboratory cell cultures by triggering a specific molecular pathway that follows RANKL signaling.

See the scientific wording

Myostatin enhances osteoclast formation in vitro by activating the SMAD2-NFATC1 signaling pathway downstream of RANKL, a key driver of bone resorption.

Why this might work

Myostatin binds to a receptor on bone-resorbing cells, triggering a chain reaction that turns on a key gene regulator called NFATC1. This regulator then switches on genes that make the cells mature into bone-eating cells, increasing bone breakdown when RANKL is present.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice

    The study found that a protein called myostatin makes bone-eating cells form more easily when another signal (RANKL) is present, by turning on a specific molecular switch (SMAD2 to NFATC1). This matches exactly what the claim said.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.